In this study, we assessed the clinicopathological features of lupus nephritis patients with renal noninflammatory necrotizing vasculopathy (NNV). A total of 142 renal biopsies with lupus nephritis were reviewed, including nine cases presented with NNV and 36 without renal vascular lesions. The comparisons of clinical, laboratory and pathological features, treatments, as well as renal outcome between the two groups were further performed. In comparison with the no renal vascular lesions group, patients with NNV changes had significantly higher proportions of noninfection leukocyturia (p = 0.013) and leukocytopenia (p = 0.042), significantly higher serum creatinine (p = 0.012), lower hemoglobin (p = 0.002) and serum C3 (p < 0.001) levels. Renal pathological activity indices and chronicity indices were significantly higher in the NNV group (p = 0.002 and p = 0.006, respectively) than those in the no vascular lesions group. Regarding renal prognosis, the presence of NNV was not a risk factor for renal outcome (p = 0.327). In conclusion, NNV was not infrequent in renal biopsies of lupus nephritis. It was commonly associated with active clinical status and proliferative glomerular lesions of lupus.
Get full access to this article
View all access options for this article.
References
1.
WeeningJJD’AgatiVDSchwartzMM. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int2004; 65: 521–530.
2.
BhathenaDBSobelBJMigdalSD. Noninflammatory renal microangiopathy of systemic lupus erythematosus (‘lupus vasculitis’). Am J Nephrol1981; 1: 144–159.
3.
AppelGBPiraniCLD’AgatiV. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol1994; 4: 1499–1515.
4.
BanfiGBertaniTBoeriV. Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis1991; 18: 240–248.
5.
GrishmanEVenkataseshanVS. Vascular lesions in lupus nephritis. Mod Pathol1988; 1: 235–241.
6.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
7.
LiangMHSocherSALarsonMGSchurPH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum1989; 32: 1107–1118.
8.
BombardierCGladmanDDUrowitzMBCaronDChangCH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35: 630–640.
9.
WangJHuWXieH. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: Mycophenolate mofetil or intravenous cyclophosphamide. Lupus2007; 16: 707–712.
10.
GinzlerEMDooleyMAAranowC. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med2005; 353: 2219–2228.
11.
ChanTMTseKCTangCSLaiKNLiFK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus2005; 14: 265–272.
12.
WangHYCuiTGHouFF. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: A prospective multi-centre observational study. Lupus2008; 17: 638–644.
13.
YuFTanYLiuGWangSXZouWZZhaoMH. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int2009; 76: 307–317.
14.
NascimentoEJSilvaAMCordeiroMT. Alternative complement pathway deregulation is correlated with dengue severity. PLoS One2009; 4: e6782–e6782.
15.
Förster-WaldlECokojaLFörsterOMaurerW. Mannose‐binding lectin: Comparison of two assays for the quantification of MBL in the serum of pediatric patients. J Immunol Methods2003; 276: 143–146.
16.
ZaduraAFTheanderEBlomAMTrouwLA. Complement inhibitor C4b-binding protein in primary Sjögren’s syndrome and its association with other disease markers. Scand J Immunol2009; 69: 374–380.
17.
SongDWuLHWangFM. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther2013; 15: R12–R12.
18.
AustinHA 3rdMuenzLRJoyceKMAntonovychTTBalowJE. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int1984; 25: 689–695.
19.
AustinHA 3rdBoumpasDTVaughanEMBalowJE. Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologic data. Kidney Int1994; 45: 544–550.
20.
CerveraRFontJShoenfeldY. European Working Party on Systemic Lupus Erythematosus: A 15-year report. Autoimmun Rev2006; 5: 549–553.
21.
CerveraRAbarca-CostalagoMAbramoviczD. Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the “Euro-Lupus Project”. Autoimmun Rev2006; 5: 180–186.
22.
BaldwinDSGluckMCLowensteinJGalloGR. Lupus nephritis. Clinical course as related to morphologic forms and their transitions. Am J Med1977; 62: 12–30.
23.
TsumagariTFukumotoSKinjoMTanakaK. Incidence and significance of intrarenal vasculopathies in patients with systemic lupus erythematosus. Hum Pathol1985; 16: 43–49.
24.
WuLHYuFTanY. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int2013; 83: 715–723.
25.
MandersonAPBottoMWalportMJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol2004; 22: 431–456.
26.
FliermanRDahaMR. Pathogenic role of anti-C1q autoantibodies in the development of lupus nephritis—a hypothesis. Mol Immunol2007; 44: 133–138.
27.
YangXWTanYYuFZhaoMH. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant2012; 27: 3552–3559.
28.
LewisMJMalikTHFossati-JimackL. Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia. Arthritis Rheum2012; 64: 2707–2718.
29.
SzekaneczZKochAE. Vascular involvement in rheumatic diseases: ‘Vascular rheumatology’. Arthritis Res Ther2008; 10: 224–224.
30.
HoussiauFAVasconcelosCD’CruzD. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis2010; 69: 61–64.
31.
AppelGBContrerasGDooleyMA. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol2009; 20: 1103–1112.
